NLE High-Risk Pregnancy & Obstetric Complications — Hypertensive & Metabolic Disorders of PregnancyStudy Notes

Hypertensive disorders in pregnancy represent a spectrum of conditions defined by blood pressure elevation, proteinuria, and end-organ involvement. Understanding the classification system is fundamental to triage, assessment, and nursing intervention priorities.

Definition and Classification:
The four main categories are gestational hypertension, preeclampsia, eclampsia, and chronic hypertension with superimposed preeclampsia. Each category carries distinct risk profiles and management implications.

Gestational Hypertension occurs when systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg is recorded after 20 weeks of gestation in a woman with previously normal blood pressure, and proteinuria is absent. Blood pressure returns to normal postpartum. While initially benign-appearing, gestational hypertension can progress to preeclampsia in up to 50% of cases, necessitating close monitoring and patient education about warning signs.

Preeclampsia is defined as gestational hypertension (BP ≥140/90 after 20 weeks) accompanied by proteinuria (≥300 mg in 24-hour urine, or a protein-to-creatinine ratio ≥0.3, or 1+ or greater on urine dipstick if quantitative testing is unavailable). Alternatively, preeclampsia may be diagnosed when severe hypertension is present without proteinuria but with new end-organ dysfunction: thrombocytopenia (platelets <100,000/μL), impaired liver function (elevated transaminases), renal insufficiency (serum creatinine >1.1 mg/dL), pulmonary edema, or cerebral/visual symptoms. This recognition is critical because many cases of preeclampsia manifest primarily as end-organ disease rather than proteinuria.

Preeclampsia with Severe Features is the designation when systolic BP reaches ≥160 mmHg or diastolic BP ≥110 mmHg, or when clinical symptoms emerge: severe, persistent headache unresponsive to analgesics; visual disturbances (blurring, scotomata, photophobia, amaurosis fugax); epigastric or right-upper-quadrant pain (indicating hepatic capsule distention); or laboratory abnormalities as listed above. The presence of severe features mandates urgent intervention and, typically, delivery.

Eclampsia is preeclampsia complicated by generalized tonic-clonic seizures not attributable to other causes. Seizures may occur antepartum (most common), intrapartum, or postpartum (within 48 hours, occasionally up to 4 weeks). Eclampsia represents medical emergency; delivery is the only definitive treatment.

Chronic Hypertension with Superimposed Preeclampsia is the highest-risk category: a woman with pre-existing hypertension (present before pregnancy or before 20 weeks) who develops new-onset or worsening proteinuria after 20 weeks, or demonstrates clinical or laboratory evidence of end-organ dysfunction. These women face markedly increased maternal and fetal mortality.

Pathophysiologic Mechanism—Vasospasm and Endothelial Dysfunction:
The fundamental pathology in preeclampsia is generalized vasospasm resulting from abnormal placentation and systemic endothelial dysfunction. In normal pregnancy, trophoblastic invasion of the spiral arteries creates low-resistance vessels that accommodate increased blood flow. In preeclampsia, this remodeling fails, leaving arteries narrowed and reactive to vasoconstrictors. The result is widespread vasoconstriction that raises blood pressure and simultaneously reduces organ perfusion.

The vasospasm affects every organ system: in the placenta, it causes poor perfusion, leading to fetal growth restriction and, if severe, placental abruption; in the kidneys, filtered load decreases while proteinuria develops from endothelial injury; in the liver, hepatocyte necrosis and subcapsular hemorrhage occur, causing epigastric pain (a clinical warning sign); in the brain, cerebral arteriolar constriction and cerebral edema lower the seizure threshold; and in the eyes, retinal arteriolar narrowing produces visual symptoms. Increased vascular permeability causes fluid to escape the intravascular space, creating peripheral and pulmonary edema, and simultaneously hemoconcentrating the blood (elevated hematocrit). Paradoxically, despite visible edema and elevated total body water, the woman is intravascularly volume-depleted, which explains why aggressive diuresis and routine IV fluid boluses are dangerous and why fluids must be administered judiciously under hemodynamic monitoring.

This distinction—intravascular volume depletion coexisting with tissue edema—is a high-yield concept for the NLE and critical for safe practice. The woman often appears "full" of fluid but lacks circulating volume.

HELLP syndrome—Hemolysis, Elevated Liver enzymes, Low Platelets—is a life-threatening variant of severe preeclampsia occurring in approximately 10–20% of women with severe preeclampsia. It can develop antepartum, intrapartum, or postpartum and represents a medical and obstetric emergency.

Clinical Presentation and Diagnosis:
Women with HELLP syndrome typically present with right-upper-quadrant or epigastric pain (from hepatic capsule distention or subcapsular hemorrhage), nausea, malaise, and general malaise disproportionate to vital sign abnormalities. Some women are remarkably calm and stable until sudden decompensation occurs. The diagnosis is confirmed by laboratory findings: evidence of hemolysis (schistocytes on blood smear, elevated LDH, low haptoglobin, elevated indirect bilirubin), elevated liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] >2× upper limit of normal), and thrombocytopenia (platelets <100,000/μL, and often <50,000/μL in severe cases).

Critical Complications:
HELLP syndrome is associated with maternal hemorrhagic complications (from severe thrombocytopenia and consumptive coagulopathy progressing to disseminated intravascular coagulation [DIC]), hepatic rupture (a catastrophic event with maternal mortality approaching 50%), renal failure from acute tubular necrosis, and placental abruption. Fetal death occurs in 5–35% of cases due to prematurity, placental insufficiency, or abruption.

Nursing Considerations:
The nurse must recognize that women with HELLP are not stable simply because they appear well. Right-upper-quadrant pain is a red flag requiring immediate investigation. Once HELLP is suspected or confirmed, avoid palpating the liver—even gentle palpation can rupture a distended, edematous liver capsule, causing rapid exsanguination. Position the woman in left lateral recumbency, administer oxygen, establish two large-bore IV lines, send blood for CBC (including differential for schistocytes), liver enzymes, bilirubin, LDH, haptoglobin, serum creatinine, coagulation studies, and type and cross; prepare for urgent delivery (usually cesarean given the obstetric and maternal emergencies this syndrome presents); and be ready to administer magnesium sulfate, antihypertensives, blood products (as platelet and clotting factor depletion progress), and ICU-level supportive care. Counsel the family that postpartum monitoring is crucial because HELLP can worsen in the immediate postpartum period.

Magnesium sulfate is the gold standard anticonvulsant in preeclampsia and eclampsia worldwide, and the NLE tests it extensively because it is a high-alert medication with a narrow therapeutic window, significant toxicity risk, and specific protocols that must be mastered.

Mechanism of Action:
Magnesium is a CNS depressant that acts as a natural calcium antagonist at the neuromuscular junction and in the central nervous system. It raises the seizure threshold by stabilizing neuronal membranes, reducing the release of acetylcholine at the myoneural junction, and decreasing cerebral vascular reactivity. Magnesium does not lower blood pressure significantly, so it is not an antihypertensive; it is used for seizure prevention/treatment and neuroprotection in preeclampsia.

Dosing Regimen:
Loading dose: 4–6 g IV diluted in at least 100 mL of isotonic fluid (usually normal saline or lactated Ringer), infused over 15–30 minutes via an IV pump (never as an IV push).
Maintenance infusion: 1–2 g/hour continuous IV infusion, typically continued for 12–24 hours postpartum (or longer if eclampsia occurred). The maintenance dose is essential because the loading dose achieves peak levels transiently; the infusion maintains therapeutic levels.

Therapeutic Serum Level:
The therapeutic serum magnesium concentration is 4–7 mEq/L (approximately 4.8–8.4 mg/dL). Levels below 4 mEq/L are subtherapeutic and do not prevent seizures; levels above 10 mEq/L are associated with severe toxicity.

Monitoring Protocol Before and During Every Dose:
The nurse must assess and document the following immediately before administering the loading dose and before each 8-hour (or facility-specific) reassessment during maintenance infusion:

1. Deep tendon reflexes (DTRs): The patellar (knee), biceps, and triceps reflexes should be normal (1+ to 2+). A brisk hyperreflexia with clonus suggests impending toxicity; absent reflexes indicate toxicity requiring immediate discontinuation.
2. Respiratory rate: Must be ≥12 breaths/minute. A rate below 12 signals respiratory depression from magnesium toxicity.
3. Urine output: Must be ≥30 mL/hour (≥720 mL/24 hours). Magnesium is renally cleared; oliguria causes drug accumulation and toxicity. Insert a Foley catheter if not already present and monitor output hourly.
4. Blood pressure: Magnesium does not lower BP, so persistent severe hypertension requires additional antihypertensives (hydralazine, labetalol, nifedipine).
5. Level of consciousness: The woman should be alert and oriented; drowsiness may indicate early toxicity.
6. Serum magnesium level: Obtain a baseline level before the loading dose and then as clinically indicated (e.g., if renal function is uncertain, if the woman is oliguric, or if toxicity is suspected). Some protocols also check levels 4–6 hours after the loading dose.

If any of these criteria are not met, HOLD the infusion and notify the physician immediately.

Signs of Magnesium Toxicity—In Order of Appearance:
Magnesium toxicity is dose-dependent and develops progressively as the serum level rises. Recognizing the sequence is critical for early intervention:

1. Loss of deep tendon reflexes (DTRs) occurs at serum levels of approximately 8–10 mEq/L. This is the earliest clinical warning sign and should prompt immediate cessation of the infusion. The patellar reflex is typically lost first; absence of both patellar and biceps reflexes indicates significant toxicity.
2. Respiratory depression (respiratory rate <12/min, shallow breathing) develops at levels around 10–12 mEq/L. This is a medical emergency because respiratory failure can rapidly ensue.
3. Oliguria (urine output <30 mL/hr or <0.5 mL/kg/hr) occurs as the kidneys fail to clear magnesium. Once oliguria is present, magnesium accumulates, and toxicity rapidly worsens.
4. Decreased level of consciousness, progressing to lethargy, somnolence, and coma.
5. Hypotension (systolic BP <90 mmHg).
6. Cardiac dysrhythmias and, at very high levels (>15 mEq/L), cardiac arrest and respiratory arrest.

Action if Toxicity is Suspected:
Immediately stop the infusion. Flush the IV line with normal saline. Notify the physician and prepare to administer the antidote.

Antidote: Calcium Gluconate
Calcium gluconate — 1 g (which is 10 mL of a 10% solution) administered IV slowly over approximately 3 minutes — directly antagonizes the neuromuscular effects of magnesium and is the reversal agent for toxicity. Calcium should be immediately available at the bedside whenever magnesium infusion is running. After administration of calcium gluconate, the magnesium infusion is discontinued, and supportive care (supplemental oxygen, airway management, IV fluids to support urine output, possible mechanical ventilation if respiratory depression is severe) is continued. Reassess DTRs, respiratory rate, and renal function, and repeat calcium if necessary. Note: Calcium gluconate is not a substitute for discontinuing the magnesium; it buys time for renal clearance and allows supportive care to stabilize the woman.

Special Considerations:

• Renal function: Women with baseline renal impairment or acute oliguria require dose reduction or avoidance; magnesium accumulates in renal failure.
• Neonatal effects: Neonates exposed to magnesium may exhibit hypotonia, poor feeding, respiratory depression, and hyporeflexia. Neonatal nurses should be informed of maternal magnesium therapy, and the newborn should be monitored closely.
• Drug interactions: Nifedipine, certain antibiotics (e.g., aminoglycosides), and other CNS depressants potentiate magnesium effects; concurrent use requires heightened vigilance.
• Parenteral routes: Magnesium sulfate is given IV in acute settings. IM administration (4–5 g in each buttock) is an option for women unable to tolerate IV lines but is more painful and less commonly used in hospital settings.

Systematic assessment and accurate diagnosis are foundational to prioritizing nursing interventions in preeclampsia and preventing progression to eclampsia or HELLP.

Clinical Assessment:
The nurse performs a comprehensive assessment with special attention to signs and symptoms of preeclampsia:

Blood Pressure Monitoring: Obtain BP in both arms, seated, after 5 minutes of rest. A rise of 15 mmHg systolic or 10 mmHg diastolic from baseline (even if BP remains <140/90) is significant and warrants closer surveillance. Automated devices are acceptable if calibrated; however, manual auscultatory BP is more reliable, especially when comparing sequential readings.

Weight and Fluid Status: Weigh the woman at each visit (ideally at the same time of day, in similar clothing). A sudden weight gain of >2 lb/week or >5 lb in 2 weeks, especially accompanied by edema, is suspicious for preeclampsia. Assess for pitting edema of the face, hands, and dependent areas (ankles); note whether swelling is generalized or localized. Ask about symptoms: tightness of rings/shoes, difficulty opening the mouth (facial edema), or puffy appearance.

Vital Signs: Tachycardia may reflect pain, anxiety, or underlying compensation (e.g., from abruption). Tachypnea may indicate pulmonary edema or acidosis. Temperature elevation is not part of preeclampsia per se (should prompt investigation for infection).

Deep Tendon Reflexes and Clonus: This is an essential examination in any woman with hypertension in pregnancy. Use a reflex hammer to elicit the patellar reflex (most reliable); normal is brisk (1+ to 2+), hyperreflexia is 3+ to 4+, and clonus is a series of rhythmic reflexes after a single stimulus (indicates severe CNS irritability). Document as: 0 = absent, 1+ = normal, 2+ = brisk, 3+ = hyperreflexia, 4+ = hyperreflexia with clonus. Clonus or 4+ reflexes are concerning signs of severe preeclampsia and indicate high seizure risk.

Symptoms and Complaints: Ask specifically about:

• Headache: character (throbbing, pressure, severity), location, duration, response to analgesics. Severe headache unresponsive to acetaminophen or ibuprofen is a red flag.
• Visual changes: blurring, dimming, flashing lights (scotomata), temporary blindness (amaurosis fugax), sensitivity to light (photophobia). These reflect retinal arteriolar spasm.
• Epigastric or right-upper-quadrant pain: "feeling of fullness," nausea, or pain with deep inspiration (hepatic capsule distention). This is ominous and suggests HELLP or impending hepatic rupture.
• Decreased fetal movement: may indicate placental insufficiency or abruption.
• Symptoms of pulmonary edema: shortness of breath, orthopnea, productive cough, chest tightness.

Urine Assessment:
Obtain a clean-catch or catheterized specimen. Dipstick for protein: 0 or trace is normal, 1+ suggests preeclampsia, 2+ or greater is significant. A 24-hour urine collection for protein quantification is more accurate; >300 mg/24 hr confirms proteinuria. Also check for glucose (may indicate diabetes), blood, and leukocytes (rule out UTI). Assess urine output: oliguria (<500 mL/24 hr, or <30 mL/hr in acute settings) is a severe feature and indicates poor renal perfusion.

Laboratory and Diagnostic Findings:

Complete Blood Count (CBC): Hematocrit is often elevated (hemoconcentration from intravascular fluid loss); a hematocrit >38–40% in a non-anemic woman is suggestive. Platelet count <100,000/μL indicates HELLP or severe preeclampsia with platelet consumption.

Coagulation Studies: Prothrombin time (PT), partial thromboplastin time (PTT), and fibrinogen. Prolonged PT/PTT or low fibrinogen (<100 mg/dL) signal coagulopathy/DIC.

Liver Enzymes: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are typically <2× the upper limit of normal in mild-to-moderate preeclampsia but elevated in HELLP. Also check total and direct bilirubin; elevation indicates hepatic dysfunction.

Renal Function: Serum creatinine (baseline in early pregnancy is ~0.4–0.6 mg/dL; a value >0.9 mg/dL, even if in the "normal" range for non-pregnant women, is elevated and indicates renal impairment); blood urea nitrogen (BUN); and uric acid (elevated in preeclampsia, particularly >5.5 mg/dL).

Lactate Dehydrogenase (LDH): Elevated LDH (>600 U/L) in conjunction with elevated creatinine and low platelets suggests hemolysis (HELLP).

Fetal Assessment:
Non-stress test (NST) to assess fetal well-being; contraction stress test or biophysical profile if NST is non-reassuring or in women at high risk for placental insufficiency. Ultrasound for estimated fetal weight, amniotic fluid volume, umbilical artery Doppler studies (if available and indicated), and signs of abruption.

NANDA Nursing Diagnoses (Prioritized by Maslow's Hierarchy):

1. Risk for injury (seizures) — related to cerebral vasospasm, elevated BP, and decreased seizure threshold.

   • Goal: The woman remains free of seizure activity and injury; safety measures are maintained.
   • Interventions: Seizure precautions (padded side rails up, suction and oxygen at bedside, emergency airway equipment accessible); reduce environmental stimuli (quiet, dim room); keep family informed of precautions; educate about warning signs.

2. Risk for ineffective cerebral/placental/renal tissue perfusion — related to vasospasm and intravascular volume depletion.

   • Goal: Vital organs maintain adequate perfusion; fetal heart rate remains reactive; urine output remains ≥30 mL/hr.
   • Interventions: Position in left lateral recumbency; restrict activity; monitor BP, fetal heart rate, and urine output continuously; administer magnesium sulfate and antihypertensives as ordered; obtain periodic lab work (creatinine, fetal monitoring studies).

3. Acute pain — related to hepatic capsule distention, headache, or contractions.

   • Goal: Pain is controlled to a tolerable level; woman reports relief.
   • Interventions: Assess pain character, severity, and location; administer analgesics as ordered (acetaminophen is safe; NSAIDs are generally avoided); use non-pharmacologic comfort measures (position changes, cool compresses, quiet environment); report severe epigastric pain immediately (possible HELLP/abruption).

4. Deficient knowledge — related to disease process, medication (magnesium sulfate), and warning signs.

   • Goal: The woman and family verbalize understanding of preeclampsia, magnesium therapy, and when to seek emergency care.
   • Interventions: Teach about preeclampsia, its risks, and the purpose of magnesium; explain monitoring and restrictions; provide written materials; discuss danger signs (headache, visual changes, epigastric pain, decreased urine output, decreased fetal movement); ensure she knows to report these immediately.

The nursing care of a woman with preeclampsia is intensive, multifaceted, and focused on preventing seizures, maintaining organ perfusion, and achieving safe delivery. Antihypertensive agents are used selectively—only when BP is ≥160/110 mmHg (severe hypertension)—to prevent maternal stroke while avoiding excessive lowering that compromises placental perfusion.

Environmental Management and Seizure Precautions:

Seizure Precautions are the cornerstone of prevention:

• Place the woman in a quiet, dimly lit private room (or the quietest area available). Sensory stimulation—loud noise, bright lights, noxious stimuli, repeated examinations—can lower the seizure threshold and precipitate eclampsia.
• Keep side rails padded and raised; ensure a mattress protector is in place.
• Position suction, oxygen, and airway equipment (oral airway, endotracheal tubes, laryngoscope) at the immediate bedside.
• Have emergency medications readily available: magnesium sulfate (loading and maintenance infusions), antihypertensives (hydralazine, labetalol), and calcium gluconate (magnesium antidote).
• Limit visitors and restrict unnecessary procedures and examinations; consolidate care (e.g., vital signs, blood draws) to minimize disruptions.
• Keep the call bell within reach; respond promptly to needs to reduce anxiety and frustration.
• Do not insert anything into the mouth during a seizure; attempting to hold the tongue or inserting an airway during a seizure risks tooth breakage and aspiration.

Positioning:
Position the woman in left lateral recumbency (left side-lying) as much as possible. This position:

• Relieves aortocaval compression, maximizing cardiac output and renal perfusion.
• Improves uteroplacental perfusion, benefiting the fetus.
• Reduces intracranial pressure (if cerebral edema is present).
• Women are often more comfortable on their left side and may rest better.

Monitoring During Magnesium Infusion:
The nurse monitors continuously:

• Vital signs (BP, heart rate, respiratory rate) every 15–30 minutes during the loading dose and at least hourly during maintenance.
• DTRs, respiratory rate, and level of consciousness before the loading dose and before each 8-hour assessment (or per facility protocol) during maintenance.
• Urine output hourly (insert Foley catheter if not present); report output <30 mL/hr immediately.
• Fetal heart rate continuously (external monitoring) or at regular intervals (NST).
• Serum magnesium level as ordered (often baseline and 4–6 hours post-loading, then periodically; more frequently if renal function is questionable or oliguria is present).

Strict Intake and Output:
Maintain a strict I&O record. Because the woman is intravascularly volume-depleted despite peripheral edema, IV fluids must be infused cautiously (usually at 75–150 mL/hr, or with a pump and strict monitoring). Avoid aggressive fluid boluses (e.g., 500–1000 mL rapidly), as these can precipitate pulmonary edema. If pulmonary edema develops, reduce IV rate, elevate the head of the bed, administer oxygen, and notify the physician (may require diuretics in conjunction with careful BP support).

Activity Restriction:
Bed rest or modified bed rest is recommended to reduce metabolic demand and allow the body to redirect resources to vital organs. Women with mild preeclampsia may be managed at home with bed rest and close outpatient follow-up; women with severe features are hospitalized for continuous monitoring.

Antihypertensive Therapy:
Antihypertensives are used judiciously—only when systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg—to reduce the risk of maternal stroke while preserving placental perfusion. The goal is not to normalize BP (which would compromise placental blood flow) but to lower it sufficiently to reduce maternal vascular risk. Typical targets are to reduce BP by 10–20% acutely.

First-Line Agents:

Hydralazine: A direct-acting vasodilator given as IV boluses.

• Dose: 5–10 mg IV over 1–2 minutes; may repeat every 20–30 minutes as needed (max usual total dose ~20 mg).
• Onset: 10–20 minutes; peak effect 20–40 minutes.
• Monitoring: Watch for maternal hypotension (target is not <120/80, as this reduces placental perfusion) and reflex tachycardia. Tachycardia >120 bpm warrants careful assessment.
• Advantage: short-acting, reversible, used for decades in pregnancy, safe for mother and fetus.

Labetalol: A combined alpha- and beta-blocker; increasingly popular because it decreases BP while maintaining or increasing placental perfusion.

• Dose: 20 mg IV initially; if BP not adequately reduced after 10 minutes, escalate: 40 mg, then 80 mg, then 160 mg at 10-minute intervals.
• Onset: 5–10 minutes; peak 10–20 minutes.
• Duration: 3–6 hours.
• Monitoring: Assess for hypotension and bradycardia; avoid in asthma or severe bradycardia. Labetalol may mask tachycardia (beta-blockade).
• Advantage: smooth BP reduction, less maternal hypotension than hydralazine, preserves placental blood flow.

Nifedipine (Calcium Channel Blocker):

• Dose: 10–20 mg orally; onset 15–30 minutes, duration 3–6 hours. Repeat dosing every 30 minutes as needed (max 120 mg/day).
• Advantage: oral route (useful if IV access is lost or woman refuses IV); no teratogenic risk even in early pregnancy.
• Caution: Do not use immediate-release sublingual nifedipine (unpredictable absorption, excessive BP drop); use oral immediate-release or long-acting formulations only if IV agents are unavailable.

Methyldopa:

• Dose: 250–500 mg orally 2–3 times daily; onset 4–6 hours, duration 12–16 hours.
• Used for chronic/long-term control in women with chronic hypertension superimposed by preeclampsia; not typically used for acute hypertension episodes.

Medications to Avoid:

• ACE inhibitors (e.g., enalapril, lisinopril) and ARBs (e.g., losartan): teratogenic, especially in the second and third trimesters; can cause fetal renal dysgenesis, oligohydramnios, and intrauterine growth restriction. Discontinue immediately upon diagnosis of pregnancy.
• Atenolol: associated with fetal growth restriction; other beta-blockers (labetalol) are preferred.
• Sodium nitroprusside: reserved for hypertensive emergencies in ICU settings; prolonged use risks cyanide toxicity.

Response to Antihypertensives:
After administering an antihypertensive, recheck BP in 15–30 minutes. If BP has not decreased by at least 10–20%, repeat the dose (or escalate as per protocol). Continue monitoring closely; do not allow BP to drop below 140/90 acutely (risk of placental hypoperfusion).

Delivery:
Delivery is the definitive treatment for preeclampsia. Timing:

• Preeclampsia without severe features before 37 weeks: expectant management with close monitoring; deliver at ≥37 weeks or earlier if complications develop.
• Preeclampsia with severe features at ≥34 weeks: delivery is typically recommended after a course of corticosteroids (if <34 weeks) for fetal lung maturity.
• Eclampsia at any gestational age: urgent delivery once the mother is stabilized (magnesium loading, airway protected, seizure precautions in place).
• Corticosteroids for fetal lung maturity: betamethasone 12 mg IM × 2 doses (24 hours apart) if <34 weeks; may be considered up to 36+6 weeks in some settings.

Route of Delivery:
Vaginal delivery is preferred if the woman is hemodynamically stable, cervix is favorable, and no other obstetric contraindication exists. Cesarean delivery is indicated if:

• Eclampsia with failed labor induction or hemodynamic instability.
• Preeclampsia with severe features at <32 weeks with non-reassuring fetal status (vaginal delivery may be unsafe given extreme prematurity).
• Placental abruption.
• Labor does not progress despite adequate induction.

Magnesium Sulfate Duration:
Continue magnesium sulfate for 12–24 hours postpartum (or longer if eclampsia occurred); some experts recommend up to 48 hours if the woman had an eclamptic seizure. Monitor carefully for postpartum eclampsia (can occur even days after delivery).

Eclamptic seizure is a medical emergency that demands immediate, calm, and coordinated nursing and medical response. The seizure itself is usually brief (1–2 minutes) but may be followed by postictal confusion, aspiration risk, and life-threatening complications for both mother and fetus. The nurse's priority is safety, airway maintenance, and preparation for delivery.

Recognizing an Eclamptic Seizure:
The seizure is typically generalized tonic-clonic: the woman may cry out, then the body stiffens (tonic phase, ~10–20 seconds), followed by rhythmic jerking of all extremities (clonic phase, ~10–30 seconds). The woman may become apneic during the seizure, and the eyes may roll back or deviate to one side. Incontinence may occur. After the seizure ends, the woman enters a postictal state—confusion, agitation, combativeness, amnesia for the event, and gradually returning consciousness over minutes to hours.

Immediate Actions During a Seizure:

1. Stay calm and call for help immediately (activate emergency call; alert obstetrician, anesthesia, pediatrics).
2. Protect from injury; do NOT restrain. Let the seizure run its course. If the woman is in bed, ensure she cannot fall. If standing, ease her to the floor (do not try to hold her upright). If possible, move nearby objects out of the way. Never attempt to hold the tongue or force anything into the mouth — this risks broken teeth, lip/tongue laceration, and aspiration of foreign objects. The tongue does not occlude the airway during a seizure.
3. Turn the head to the side (if possible without using force) to allow secretions (saliva, blood) to drain and reduce aspiration risk. Do this gently; do not force the jaw open.
4. Apply supplemental oxygen as soon as the seizure ends (the woman was apneic during the seizure and is hypoxic).
5. Prepare for and perform suctioning after the seizure to clear secretions from the airway.
6. Assess level of consciousness and vital signs once the seizure has ended. The woman will be confused and combative; speak calmly and identify yourself. Reorient her to time, place, and person repeatedly.
7. Assess the fetus: obtain fetal heart rate immediately post-seizure (may be slow initially due to hypoxia; typically recovers within minutes if resuscitation is effective).
8. Insert or verify IV access (if not already present, now is the time). Have two large-bore IVs if possible.
9. Prepare for magnesium loading (if not already infusing): 4–6 g IV over 15–30 minutes to prevent recurrent seizures. Even if magnesium was already being infused, reassess dose adequacy and continue/adjust as needed.
10. Check for injuries from the seizure: tongue lacerations, lip lacerations, head trauma, aspiration, or obstetric complications (premature rupture of membranes, placental abruption, preterm labor).

Post-Seizure Assessment:

• Airway: Is the woman breathing effectively? Is O2 saturation adequate (≥95%)? Is suctioning needed?
• Breathing and circulation: Check BP (may be transiently elevated post-seizure), heart rate, and respiratory effort.
• Neurologic status: Is she alert and oriented? Any focal deficits (facial droop, arm weakness, speech difficulty—suggesting stroke)? Any severe headache, visual changes?
• Obstetric status: Fetal heart rate, contractions, vaginal bleeding/fluid, abdominal tenderness (abruption?), status of membranes.

Medication and Monitoring:
Magnesium sulfate loading (if not already given) is administered immediately. The woman is monitored on continuous fetal heart rate monitoring and pulse oximetry. BP and DTRs are checked; if already on magnesium, verify that toxicity is not present. Labs (CBC, coagulation studies, renal function, liver enzymes) are obtained to assess for HELLP or DIC.

Preparation for Delivery:
Once the mother is stabilized—airway is secure, magnesium loading is complete, fetal heart rate is reassuring—the team plans for delivery. The urgency depends on gestational age and clinical stability:

• At term (≥37 weeks) with eclampsia: vaginal delivery is attempted if the cervix is favorable and labor progresses; if not, cesarean delivery is performed.
• Preterm (<37 weeks) with eclampsia: delivery is still indicated (eclampsia worsens with expectant management), but route may be vaginal (if rapid cervical change is likely) or cesarean if preterm is <32 weeks or cervix unfavorable.
• Regional anesthesia (spinal/epidural) is preferred if delivery is surgical, as it avoids airway manipulation and general anesthesia induction (which risk aspiration and maternal complications). However, platelet count must be adequate (typically ≥70,000 for epidural; some recommend ≥50,000 for spinal).

Family Communication:
Inform the family that the seizure, while frightening, was managed, the mother is now stable, and the plan is for delivery to prevent recurrence. Explain that the newborn may be admitted to the NICU for monitoring (prematurity, magnesium exposure, maternal illness effects), but most eclamptic pregnancies result in healthy babies once delivered.

Documentation:
Document the seizure event in detail: time of onset and duration, characteristics (generalized vs. focal), postictal state, interventions, and response. Note fetal heart rate pre- and post-seizure and any obstetric changes observed.

Gestational diabetes mellitus (GDM) is carbohydrate intolerance first recognized during pregnancy, typically in the second or third trimester. It is one of the most common medical complications of pregnancy, affecting 2–10% of pregnant women (depending on screening protocols and population risk factors). GDM has significant implications for mother and fetus during pregnancy and for long-term metabolic health postpartum.

Pathophysiology:
Normal pregnancy induces "physiologic insulin resistance" driven by placental hormones—particularly human placental lactogen (hPL), progesterone, and cortisol—which antagonize maternal insulin action and increase maternal fasting glucose and postprandial hyperglycemia. In non-pregnant women, the pancreas readily compensates by increasing insulin secretion. In GDM, the pancreatic beta cells cannot generate sufficient insulin to overcome this resistance, resulting in maternal hyperglycemia.

The fetal pancreas responds to maternal hyperglycemia by increasing fetal insulin secretion (fetal hyperinsulinemia). Insulin acts as a growth factor; fetal hyperinsulinemia stimulates fetal growth, resulting in macrosomia (birth weight >4,000 g or >4,500 g, depending on definition). Macrosomia increases the risk of shoulder dystocia (entrapment of the fetal shoulder behind the maternal pubic symphysis), which can cause brachial plexus injury (Erb's palsy) and other trauma.

After delivery, the maternal glucose supply is abruptly cut, but the hyperinsulinemic fetus continues to secrete high levels of insulin, causing neonatal hypoglycemia in the first hours to days of life. Additionally, maternal hyperglycemia may delay fetal lung maturation, increasing the risk of respiratory distress syndrome. Maternal hyperglycemia also increases polycythemia and hyperbilirubinemia in the newborn.

Risk Factors for GDM:

• Maternal obesity (BMI ≥30 kg/m²) — the strongest modifiable risk factor.
• Age ≥25 years (some guidelines use ≥35 years).
• Family history of diabetes (parent or sibling with type 2 diabetes).
• Previous GDM or previous macrosomic infant (birth weight >4,000–4,500 g).
• Polycystic ovary syndrome (PCOS).
• Ethnic/racial groups with higher diabetes prevalence: Hispanic, African American, Native American, Asian/Pacific Islander, and Filipino women (relevant to Philippine context).
• Sedentary lifestyle and poor diet.

Screening and Diagnosis:

Universal Screening at 24–28 Weeks:
All pregnant women (except those at very low risk, as defined by individual guidelines) undergo GDM screening at 24–28 weeks.

1. 50-gram glucose challenge test (GCT): A non-fasting 50 g oral glucose solution is given; plasma glucose is drawn at 1 hour. If the 1-hour glucose is ≥140 mg/dL, a 3-hour diagnostic oral glucose tolerance test (OGTT) is performed. (Some institutions use a threshold of ≥135 mg/dL to increase sensitivity.)

2. 3-hour, 100-gram OGTT (diagnostic test): Performed after an 8–12 hour fast. The woman ingests 100 g of glucose; plasma glucose is measured at fasting, 1 hour, 2 hours, and 3 hours.

   • Fasting: <95 mg/dL (or <100 mg/dL, depending on criteria)
   • 1-hour: <180 mg/dL (or <190 mg/dL)
   • 2-hour: <155 mg/dL (or <165 mg/dL)
   • 3-hour: <140 mg/dL (or <145 mg/dL)
   • Diagnosis: Two or more values meeting or exceeding the threshold = GDM. Some institutes require only one elevated value for diagnosis (varying criteria among guidelines).

Alternative: 2-hour, 75-gram OGTT:
Some centers use this (WHO standard), with thresholds of fasting <92 mg/dL, 1-hour <180 mg/dL, 2-hour <153 mg/dL (one value elevated = GDM).

Glycemic Targets During Pregnancy:
Once GDM is diagnosed, self-monitoring blood glucose is initiated. Targets are:

• Fasting glucose: <95 mg/dL (some guidelines <90 mg/dL)
• 1-hour postprandial: <140 mg/dL
• 2-hour postprandial: <120 mg/dL

These targets are stricter than non-pregnant diabetes targets because the goal is to minimize fetal hyperglycemia and associated complications.

Management of GDM:

First-Line: Medical Nutrition Therapy (MNT) and Exercise:
The cornerstone of GDM management is diet and exercise; 70–80% of women with GDM achieve glycemic control with lifestyle measures alone.

• Carbohydrate control: Distribute carbohydrates evenly across meals and snacks; emphasize complex carbohydrates (whole grains, legumes, vegetables) over simple sugars. A typical regimen provides 40–50% of calories from carbohydrates, distributed as ~130 g carbs at breakfast, 130 g at lunch, 130 g at dinner, and 15 g at each of 2–3 snacks (exact amounts individualized by dietitian).
• Protein and fat: Adequate protein (1.1–1.3 g/kg/day) and moderate fat intake help stabilize blood glucose.
• Frequent small meals: Eating 5–6 smaller meals rather than 3 large meals reduces post-meal glucose spikes.
• Physical activity: At least 150 minutes/week of moderate-intensity aerobic activity (e.g., walking, swimming, cycling) plus resistance training, tailored to the woman's fitness level and pregnancy status. Activity should begin soon after GDM diagnosis and continue throughout pregnancy.
• Weight management: Modest weight gain (not weight loss) during pregnancy; avoid excessive caloric restriction, which can cause ketonuria.
• Dietary supplements: Some evidence supports myo-inositol supplementation (2–4 g/day) and omega-3 fatty acids to improve insulin sensitivity, but these are not standard; consult guidelines.

Second-Line: Insulin Therapy:
If diet and exercise do not achieve targets after 2–3 weeks of adherence (or if fasting hyperglycemia is present from the start), insulin is initiated. Insulin is the safest and most effective glucose-lowering agent in pregnancy because:

• It does not cross the placenta (too large a molecule); thus, fetal insulin exposure is only from increased fetal insulin secretion in response to maternal glucose, not exogenous insulin.
• It has a long track record of safety in pregnancy (used since the 1920s).
• It is effective at achieving targets.

Typically, a basal-bolus regimen is used:

• NPH insulin (Humulin N, Novolin N): intermediate-acting, given as a long-acting basal dose once or twice daily.
• Rapid-acting insulin (lispro [Humalog], aspart [NovoLog], glulisine [Apidra]): given with meals.
• Dosing: Usually starts at 0.7–1.0 unit/kg/day, distributed as ~50% basal and ~50% mealtime doses, then titrated based on blood glucose logs.

Oral Agents:
Some oral agents are used in GDM (where available):

• Metformin: 1,500–2,550 mg/day divided; reduces hepatic glucose production and improves insulin sensitivity. Growing evidence supports its use; does not cross placenta significantly. Some recommend metformin as first-line because it aids with long-term weight management and is less burdensome than insulin injections.
• Glyburide (Micronase): a sulfonylurea that stimulates beta-cell insulin secretion; dosing 2.5–15 mg/day divided. Historically used and remains acceptable in many guidelines, though some data suggest slightly higher adverse perinatal outcomes than insulin.
• Acarbose or other alpha-glucosidase inhibitors: delay carbohydrate absorption; less commonly used but an option for mild hyperglycemia.

However, insulin remains the standard of care in most guidelines, particularly for fasting hyperglycemia. Oral agents are used when insulin is unavailable, unaffordable, or the woman strongly prefers an oral route.

Self-Monitoring Blood Glucose (SMBG):
The woman is taught to:

• Use a reflectance meter (glucose meter) to check capillary blood glucose at home.
• Test fasting (before breakfast) and 1–2 hours after the start of each meal (4–7 daily checks).
• Keep a detailed log and bring it to every appointment.
• Recognize patterns: if fasting glucose is consistently elevated, basal insulin is increased; if post-breakfast glucose is high, mealtime insulin is increased, etc.
• Recognize signs of hypoglycemia (shakiness, sweating, palpitations, confusion, altered speech) and treat with 15 g of fast-acting carbohydrate (4 oz juice, 3–4 glucose tablets, 1 tbsp honey).

Fetal Monitoring:

• Serial ultrasounds to assess fetal growth, amniotic fluid volume, and signs of macrosomia.
• Non-stress testing (NST) starting at 28 weeks (or earlier if poor glycemic control or other complications).
• Contraction stress test or biophysical profile if NST is non-reassuring or if the woman has concurrent preeclampsia or other complications.

Delivery Timing and Mode:

• Timing: Delivery at 39–40 weeks is typical (some experts induce at 38–39 weeks if insulin is required, due to increased stillbirth risk; others recommend expectant management to near-term with close monitoring).
• Route: Vaginal delivery is preferred if no obstetric contraindication. Induction of labor is often recommended to reduce the risk of macrosomia-related complications and stillbirth.
• Fetal weight estimates and maternal pelvic adequacy should be assessed; if estimated fetal weight is >4,500 g (or >4,000 g in some cases), cesarean delivery may be recommended to avoid shoulder dystocia.

Newborn Management:

• Breastfeeding: Initiated early and frequently (within 1 hour of delivery, then every 2–3 hours) to provide glucose and reduce neonatal hypoglycemia risk.
• Frequent glucose monitoring: Capillary blood glucose checks at 1 hour of life, before each feeding, and periodically (per institutional protocol) in the first 24–48 hours to detect hypoglycemia (threshold typically <40–50 mg/dL in the first few hours, then <70 mg/dL).
• IV dextrose: If breastfeeding is unsuccessful or glucose remains <40 mg/dL despite feeding, IV dextrose (10% dextrose at ~5–10 mL/kg/hr) is given.
• NICU admission: Infants with persistent hypoglycemia, respiratory distress, hyperbilirubinemia, or prematurity are admitted for monitoring and treatment.

Postpartum Follow-Up:
GDM resolves in ~95% of women immediately postpartum (glucose-regulating mechanisms normalize). However, women with GDM have a 25–50% lifetime risk of developing type 2 diabetes. Therefore:

• Fasting glucose or 2-hour OGTT is obtained at 6–12 weeks postpartum to confirm resolution and screen for undiagnosed type 2 diabetes.
• Annual screening (fasting glucose or HbA1c) is recommended long-term.
• Intensive lifestyle counseling: diet, exercise, weight loss (if needed), smoking cessation.
• Family planning: Women with prior GDM who plan future pregnancies should be counseled about GDM risk in future pregnancies (recurrence ~30–50%) and encouraged to maintain healthy weight and activity before conception.

Hyperemesis gravidarum is severe, persistent nausea and vomiting during pregnancy that results in dehydration, electrolyte imbalance, weight loss exceeding 5% of pre-pregnancy weight, and ketonuria. It is distinct from ordinary "morning sickness" (mild nausea affecting ~50% of pregnancies in the first trimester, usually resolving by 14–16 weeks) and occurs in ~0.5–2% of pregnancies. The condition is more common in multiple gestations, molar pregnancy, and PCOS and is associated with high hCG levels.

Pathophysiology:
The exact mechanism remains unclear, but proposed factors include:

• High human chorionic gonadotropin (hCG): hCG peaks in the first trimester and declines thereafter; the timing correlates with hyperemesis severity. Women carrying multiple fetuses or molar pregnancy (which produce very high hCG) have higher hyperemesis risk.
• Gastrointestinal dysmotility: altered gastric emptying and esophageal motility contribute.
• Metabolic factors: elevated estrogen, progesterone, and altered serotonin metabolism.
• Psychological factors: stress, anxiety, and previous eating disorders may exacerbate symptoms, though hyperemesis is not primarily psychiatric.
• Helicobacter pylori infection: some studies link H. pylori to hyperemesis; eradication may help.

Clinical Presentation and Assessment:

Symptom Severity:
Vomiting is frequent (may occur dozens of times daily), triggered by smells, tastes, specific foods, movement, or spontaneously. Unlike typical nausea, hyperemesis vomiting prevents adequate oral intake and nutrition.

Dehydration Signs:

• Dry mucous membranes, lips, and tongue (compare to baseline)
• Poor skin turgor (pinched skin returns slowly to normal)
• Sunken eyes
• Tachycardia (>100 bpm)
• Postural hypotension (systolic BP drops ≥10–15 mmHg when moving from lying to sitting/standing)
• Dizziness or lightheadedness

Weight Loss:
Document pre-pregnancy weight and weigh the woman; >5% weight loss is significant. Prolonged weight loss increases risk of fetal growth restriction.

Electrolyte and Acid-Base Disturbances:

• Hypokalemia: loss of potassium from vomiting; manifests as muscle weakness, cardiac dysrhythmias, polyuria (paradoxically, low K+ increases urine output and worsens hypokalemia).
• Hyponatremia: loss of sodium and free water retention; causes confusion, headache, seizures (severe).
• Metabolic alkalosis: loss of gastric acid (HCl) without replacement; the body compensates by retaining CO2 (hypoventilation), but renal bicarbonate reabsorption is enhanced, perpetuating alkalosis. Alkalosis causes hypokalemia to worsen (K+ shifts intracellularly).
• Dehydration-induced azotemia: elevated BUN, creatinine (from volume depletion, not renal disease).
• Metabolic acidosis (if starvation ketonosis): prolonged vomiting with inadequate nutrient intake causes ketone body formation; arterial pH drops, HCO3 falls.

Urine Findings:

• Ketonuria (positive urine ketones) indicates starvation or inadequate carbohydrate intake; this is a key finding in hyperemesis.
• Concentrated urine (high specific gravity, dark color) from dehydration.

Associated Complications:

• Wernicke encephalopathy: thiamine (vitamin B1) deficiency from prolonged vomiting causes confusion, ataxia, ophthalmoplegia, and permanent neurologic damage if not treated. Critical to replenish thiamine early.
• Hepatic dysfunction: elevated liver enzymes and jaundice (rare but serious).
• Coagulopathy: from vitamin K deficiency (fat-soluble vitamin loss).
• Fetal effects: if severe and prolonged, intrauterine growth restriction and preterm birth are risks.

Diagnostic Workup:

• Laboratory studies: Serum electrolytes (sodium, potassium, chloride, bicarbonate), BUN, creatinine, uric acid, liver enzymes (ALT, AST), bilirubin, amylase (pancreatitis?), albumin (nutritional status), and blood glucose (hyperemesis can precipitate hypoglycemia or hyperglycemia).
• Urinalysis: ketonuria, specific gravity (concentration), glucose (rule out diabetes), blood/WBC (rule out UTI/pyelonephritis, which can exacerbate nausea).
• Ultrasound: confirm dates, rule out molar pregnancy or multiple gestation (high hCG triggers hyperemesis).
• Thyroid function (TST, free T4): pregnancy naturally increases thyroid hormone; marked elevation (as in gestational transient thyroiditis) may worsen nausea. However, routine TSH is often normal in hyperemesis.
• Upper endoscopy: if vomiting is refractory or atypical, to rule out peptic ulcer disease, gastritis, GERD, or outlet obstruction (rare).

Nursing Diagnosis and Care Plan:

Primary NANDA Diagnoses:

1. Nausea — related to elevated hCG, gastric dysmotility, and metabolic factors.

   • Goal: Nausea is minimized; woman reports improved tolerance of fluids/foods.
   • Interventions: Small, frequent, dry, bland foods (crackers, toast, plain potatoes); cold foods (often better tolerated than hot); separate solids from liquids (drink fluids between meals, not with food); avoid triggers (smells, specific foods); provide antiemetics as ordered (see below); position upright for 30 minutes after eating; provide frequent mouth care (reduce nausea from stale taste).

2. Deficient fluid volume — related to excessive vomiting and inadequate intake.

   • Goal: Fluid volume is restored; vital signs are stable; urine output is normal.
   • Interventions: Establish IV access (18–20 gauge catheter for rapid fluid infusion); administer isotonic IV fluids (usually normal saline or lactated Ringer); correct electrolyte abnormalities (potassium and magnesium replacement if hypokalemic or hypomagnesemic); monitor intake/output hourly; weigh daily; assess vital signs, skin turgor, mucous membranes; educate about sipping fluids slowly when tolerating oral intake.

3. Imbalanced nutrition: less than body requirements — related to persistent vomiting and inadequate oral intake.

   • Goal: Nutritional status is maintained; weight loss slows; fetal growth remains appropriate.
   • Interventions: NPO initially (rest the GI tract); transition to clear fluids, then to small sips of ginger ale, broth, or electrolyte solutions; advance slowly to bland foods (crackers, cereal, applesauce); coordinate with dietitian for meal planning; consider parenteral nutrition (PN) or nasogastric feeding with a semi-elemental formula if oral intake remains inadequate despite antiemetics; monitor pre-albumin, albumin, and weight trends.

4. Risk for injury (seizures from hyponatremia, arrhythmias from hypokalemia) — related to electrolyte imbalances.

   • Goal: Electrolytes are normalized; woman is free of complications (seizures, cardiac dysrhythmias).
   • Interventions: Monitor serum electrolytes frequently (daily if hospitalized); replace potassium carefully (risk of cardiac arrhythmias with rapid infusion); monitor cardiac rhythm if K+ is severely low (<2.5 mEq/L); perform frequent neuro checks (confusion, hallucinations, headache from hyponatremia); prevent hypernatremia correction too rapidly (risk of cerebral edema); administer thiamine 100 mg IV daily (before dextrose-containing fluids to prevent Wernicke encephalopathy).

5. Deficient knowledge — related to management strategies, medication, and danger signs.

   • Goal: Woman and family understand hyperemesis causes, management, and warning signs to report.
   • Interventions: Teach dietary strategies (small frequent meals, separation of fluids/solids, bland foods, cold preferences); explain medication use and side effects; discuss danger signs (persistent vomiting despite treatment, decreased urine output, confusion, palpitations—indicating need for emergency evaluation); provide written materials; support group referrals or online resources; reassure that hyperemesis usually resolves by 16–20 weeks and that fetal outcomes are generally good if managed appropriately.

Medication Management (Antiemetics):

First-Line:

• Pyridoxine (Vitamin B6): 25–50 mg orally three times daily. Safe, well-tolerated, and FDA Category A. Effect is modest but adds to combination therapy. Often combined with doxylamine (see below).
• Doxylamine: 12.5 mg orally at bedtime (and morning/afternoon if needed, max 25 mg/day). An antihistamine; FDA Category A for pregnancy. Sedation is common. The combination of pyridoxine + doxylamine (Diclegis, Diclectin in Canada) is FDA-approved for morning sickness and is often used for hyperemesis.

Second-Line:

• Metoclopramide (Reglan): 10 mg IV/IM/PO three times daily (or 10 mg via IV infusion). Enhances gastric emptying and blocks dopamine centrally. Risk of tardive dyskinesia with prolonged use (>3 months), though risk is lower in pregnancy (limited data). FDA Category B.
• Promethazine (Phenergan): 12.5–25 mg IV/IM/PO every 4–6 hours. A phenothiazine antihistamine; sedating. FDA Category C (some sources: Category B). Used as second- or third-line.
• Ondansetron (Zofran): 4–8 mg IV/PO every 8 hours (or 16 mg daily). A 5-HT3 antagonist; highly effective for postoperative/chemotherapy-induced nausea but less evidence in hyperemesis per se. FDA Category B. No increased teratogenic risk.

Third-Line (if refractory):

• Corticosteroids: methylprednisolone 16 mg daily × 3 days, then taper, or prednisolone 40 mg daily × 3–5 days, then taper. Used in severe, refractory hyperemesis; risks include slightly increased cleft palate risk in first trimester (use only if severe) and immunosuppression. Meta-analyses suggest benefit.
• Mirtazapine: a tricyclic antidepressant with antihistamine properties; 15 mg at bedtime. Less common but reported effective in some cases; FDA Category C.

Supportive Care:

• Thiamine supplementation: 100 mg IV daily (or 100 mg PO daily) to prevent Wernicke encephalopathy. Give thiamine before dextrose-containing fluids (dextrose can precipitate Wernicke if thiamine stores are depleted).
• Nutritional support: Enteral nutrition (nasogastric feeding tube with semi-elemental formula) if oral intake remains <50% of goal after 1–2 weeks despite antiemetics. Parenteral nutrition is reserved for prolonged refractory hyperemesis (>2–3 weeks unresponsive to all measures).

Hospitalization Indications:

• Severe dehydration (orthostatic hypotension, tachycardia >110, poor skin turgor, concentrated urine).
• Significant electrolyte disturbances (K+ <3 mEq/L, Na+ <130 mEq/L, severe metabolic alkalosis).
• Weight loss >10% of pre-pregnancy weight.
• Inability to maintain oral nutrition despite outpatient antiemetic trials.
• Signs of Wernicke encephalopathy (confusion, ataxia, eye movement abnormalities).
• Hospitalization is typically 3–5 days for IV hydration, electrolyte correction, antiemetic optimization, and advancement of diet.

Discharge and Outpatient Follow-Up:
Upon discharge (or in outpatient management):

• Continue antiemetics at optimized doses.
• Follow dietary recommendations (small, frequent, bland meals; separate fluids).
• Weekly weight checks; report loss >2 lb/week.
• Labs (electrolytes, BUN, creatinine) at 1 week, then as needed.
• Dietitian follow-up for meal planning and nutritional counseling.
• OB follow-up every 1–2 weeks to monitor weight, vital signs, and fetal well-being (ultrasound at regular intervals).
• Reassure that hyperemesis typically resolves by 16–20 weeks; if it persists beyond 20 weeks, investigate alternative diagnoses (peptic ulcer disease, pancreatitis, hepatic disease, psychiatric disorders).

Fetal Outcomes:
When hyperemesis is managed appropriately (fluids, electrolytes, nutrition, antiemetics), fetal outcomes are generally good. Preterm birth and fetal growth restriction are risks if hyperemesis is severe and prolonged but are less common with modern management.